Vaxcyte (PCVX) CFO sells 10K shares under 10b5-1 plan, holds 166K+

Rhea-AI Filing Summary

Vaxcyte, Inc. President and CFO Andrew Guggenhime reported a combination of option exercise and share sale. On June 18, 2026, he exercised stock options for 10,000 shares of common stock at $5.35 per share and sold 10,000 shares of common stock at $53.00 per share in an open-market transaction.

The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted March 4, 2026. Following these transactions, he holds 104,395 shares of common stock directly and 61,850 shares indirectly through ALG 2025 GRAT HOLDINGS LLC, tied to a grantor retained annuity trust. The option related to these 10,000 shares is fully vested and exercisable and has now been exercised.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($530,000)

Net Sell 4 txns

Insider GUGGENHIME ANDREW

Role PRESIDENT AND CFO

Sold 10,000 shs ($530K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$5.35	$54K
Sale	Common Stock	10,000	$53.00	$530K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 236,827 shares (Direct, null); Common Stock — 114,395 shares (Direct, null); Common Stock — 61,850 shares (Indirect, See Footnote)

Footnotes (1)

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. Option is fully vested and exercisable.

Key Figures

Shares sold: 10,000 shares Sale price: $53.00/share Options exercised: 10,000 shares +4 more

7 metrics

Shares sold 10,000 shares Common stock sold at $53.00 on June 18, 2026

Sale price $53.00/share Open-market sale of common stock

Options exercised 10,000 shares Stock option exercise on June 18, 2026

Exercise price $5.35/share Stock Option (right to buy) conversion price

Direct holdings after 104,395 shares Common stock directly owned following transactions

Indirect holdings 61,850 shares Common stock held via ALG 2025 GRAT HOLDINGS LLC

Option expiration May 11, 2030 Expiration date of exercised stock option grant

Key Terms

Rule 10b5-1 trading plan, grantor retained annuity trust, Stock Option (right to buy), annuitant, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

grantor retained annuity trust financial

"100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee."

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise or conversion price of 5.3500 per share."

annuitant financial

"the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee."

indirect ownership financial

"Shares are held by ALG 2025 GRAT HOLDINGS LLC, indicating indirect ownership through this entity."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GUGGENHIME ANDREW

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		M		10,000	A	$5.35	114,395	D
Common Stock	06/18/2026		S(1)		10,000	D	$53	104,395	D
Common Stock								61,850	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.35	06/18/2026		M			10,000	(3)	05/11/2030	Common Stock	10,000	$0	236,827	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.

2. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.

3. Option is fully vested and exercisable.

Remarks:

	Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Vaxcyte (PCVX) report for Andrew Guggenhime?

Vaxcyte reported that President and CFO Andrew Guggenhime exercised options for 10,000 common shares and sold 10,000 common shares on June 18, 2026. These moves updated both his direct holdings and his overall equity exposure in the company.

How many Vaxcyte (PCVX) shares did the CFO sell and at what price?

The CFO sold 10,000 shares of Vaxcyte common stock at $53.00 per share. This open-market sale was disclosed in the Form 4 and was executed under a pre-established Rule 10b5-1 trading plan adopted earlier in 2026.

What stock options did the Vaxcyte (PCVX) CFO exercise in this Form 4?

Andrew Guggenhime exercised stock options covering 10,000 shares of Vaxcyte common stock at a $5.35 exercise price. The option is described as fully vested and exercisable, and the exercise converted these derivative rights into actual common shares.

How many Vaxcyte (PCVX) shares does the CFO own after the reported transactions?

After the reported activity, the CFO directly owns 104,395 shares of Vaxcyte common stock. He also indirectly holds 61,850 shares through ALG 2025 GRAT HOLDINGS LLC, which is associated with a grantor retained annuity trust where he serves as annuitant and trustee.

Was the Vaxcyte (PCVX) CFO’s share sale under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the 10,000-share sale was effected under a Rule 10b5-1 trading plan adopted on March 4, 2026. Such plans pre-schedule trades, making the timing more routine and less reflective of short-term market views.

How are the Vaxcyte (PCVX) CFO’s indirect share holdings structured?

The Form 4 reports 61,850 shares held indirectly by ALG 2025 GRAT HOLDINGS LLC. All interests in this LLC are owned by a grantor retained annuity trust, where the CFO is both annuitant and trustee, providing indirect beneficial ownership of these shares.